COPLEY/FDA INVESTIGATION OF ALBUTEROL CONTAMINATION
COPLEY/FDA INVESTIGATION OF ALBUTEROL CONTAMINATION is focusing on the packaging process for the 0.5% albuterol solution for inhalation. The post-recall review of the problem was facilitated because of the presence of FDA investigators at the time the contamination was initially discovered. FDA inspectors were at Copley's facilities conducting an unrelated, general GMP compliance inspection, checking the validation of three products and doing a preapproval clearance for five other products.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth